Sign In
Buy NKTR
$59.23
+0.670 (+1.14%)
At Close: Jun 03, 2026
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Xeris Pharmaceuticals (XERS) Gets a Buy Rating from Mizuho Securities
12:56pm, Friday, 01'st May 2020
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS), with a price target of $14.00. The
Xeris Pharmaceuticals (XERS) Gets a Buy Rating from Mizuho Securities
12:56pm, Friday, 01'st May 2020
In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on Xeris Pharmaceuticals (XERS – Research
Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline
04:33pm, Thursday, 30'th Apr 2020
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline
04:33pm, Thursday, 30'th Apr 2020
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mizuho Securities Maintains a Buy Rating on Sarepta Therapeutics (SRPT)
08:11am, Thursday, 30'th Apr 2020
Mizuho Securities analyst Difei Yang maintained a Buy rating on Sarepta Therapeutics (SRPT) today and set a price target of $183.00. The company's shares
Mizuho Securities Maintains a Buy Rating on Sarepta Therapeutics (SRPT)
08:10am, Thursday, 30'th Apr 2020
Mizuho Securities analyst
Difei Yang
maintained a
Buy
rating on Sarepta Therapeutics (
SRPT
–
Research Report
) today and set a price target of
$183.00
. The company’s shares closed last Wednesday
Schmetterlinge anlocken - Schmetterlinge - Metamorphose und Futterpflanzen in Bildern
06:12am, Thursday, 30'th Apr 2020
Wir zeigen die vier Stadien der Verwandlung und welche Pflanzen Schmetterlinge anlocken und Raupen zum fressen brauchen.
Earnings Preview: Nektar Therapeutics (NKTR) Q1 Earnings Expected to Decline
12:00am, Thursday, 30'th Apr 2020
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the first quarter 2020 on Thursday, May 7, 2020, after the close of U.S.-based financial markets. Howard Robin, President and
Biodiversität auf dem Balkon - Artenreich, pflegeleicht, essbar? - Tipps für jeden Balkontypen
06:42am, Tuesday, 28'th Apr 2020
Egal ob Urban-Gardening-Freak oder Gärtner-Muffel - diese Tipps haben für jeden Balkonbesitzer etwas dabei.
Nektar Therapeutics (NASDAQ:NKTR) Earns Buy Rating from Analysts at Benchmark
08:52am, Saturday, 25'th Apr 2020
Benchmark started coverage on shares of Nektar Therapeutics (NASDAQ:NKTR) in a research report sent to investors on Wednesday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a
Head to Head Survey: Eli Lilly And Co (NYSE:LLY) versus Syros Pharmaceuticals (NYSE:SYRS)
06:28am, Saturday, 25'th Apr 2020
Eli Lilly And Co (NYSE:LLY) and Syros Pharmaceuticals (NASDAQ:SYRS) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their r
Outlook on the Worldwide Polymer-Drug Conjugate Industry to 2025 - by Manufacturers, Regions, Technology & Application
11:33am, Friday, 24'th Apr 2020
Dublin, April 24, 2020 -- The "Polymer-Drug Conjugate Market Insights 2020, Analysis and Forecast Global and Chinese Market to 2025, by Manufacturers, Regions, Technology,.
Sarepta Therapeutics (SRPT) Received its Third Buy in a Row
08:13am, Thursday, 23'rd Apr 2020
After Cowen & Co. and RBC Capital gave Sarepta Therapeutics (NASDAQ: SRPT) a Buy rating last month, the company received another Buy, this time from
